Genmab A (GMAB) Non-Current Debt (2019 - 2026)
Genmab A's (GMAB) quarterly Non-Current Debt came in at $4.9 billion in Q1 2026, up 3724.03% YoY from $129.0 million in Q1 2025, and down 1.36% on a QoQ basis from $5.0 billion in Q4 2025.
Genmab A (GMAB) Non-Current Debt (2019 - 2026) Analysis & Trends
Genmab A (GMAB) has 4 years of Non-Current Debt data on file, last reported at $4.9 billion in Q1 2026.
- Quarterly Non-Current Debt rose 3724.03% year-over-year to $4.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 billion (up 3724.03% YoY) and the FY2025 annual result came in at $5.0 billion, changed N/A from the prior year.
- Non-Current Debt fell to $4.9 billion in Q1 2026, from $5.0 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $5.0 billion in Q4 2025 to a low of $129.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 4.84 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.84 Bn |
| Mar 31, 2026 | 4.93 Bn |
| Dec 31, 2025 | 5.00 Bn |
| Mar 31, 2025 | 129.00 Mn |
| Sep 30, 2020 | 295.00 Mn |
| Dec 31, 2019 | 155.00 Mn |
| Sep 30, 2019 | 157.61 Mn |